Evidence map›Paper›PMID 36551739›Full record

ArticleCancers2022

High-Frequency Nanosecond Bleomycin Electrochemotherapy and its Effects on Changes in the Immune System and Survival.

Austėja Balevičiūtė, Eivina Radzevičiūtė, Augustinas Želvys, Veronika Malyško-Ptašinskė, Jurij Novickij, Auksė Zinkevičienė, Vytautas Kašėta, Vitalij Novickij, Irutė Girkontaitė

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Reversible electroporation for cancer therapy.The British journal of radiology · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Austėja BalevičiūtėInstitute of Environmental Medicine, Toxicology Unit, Karolinska Institutet, 171 77 Stockholm, Sweden.ORCID 0000-0003-2179-5394
Eivina RadzevičiūtėDepartment of Immunology, State Research Institute Centre for Innovative Medicine, 13102 Vilnius, Lithuania.ORCID 0000-0003-4588-7576
Augustinas ŽelvysDepartment of Immunology, State Research Institute Centre for Innovative Medicine, 13102 Vilnius, Lithuania.
Veronika Malyško-PtašinskėFaculty of Electronics, Vilnius Gediminas Technical University, 10223 Vilnius, Lithuania.
Jurij NovickijFaculty of Electronics, Vilnius Gediminas Technical University, 10223 Vilnius, Lithuania.
Auksė ZinkevičienėDepartment of Immunology, State Research Institute Centre for Innovative Medicine, 13102 Vilnius, Lithuania.
Vytautas KašėtaDepartment of Biomodels, State Research Institute Centre for Innovative Medicine, 11342 Vilnius, Lithuania.ORCID 0000-0001-9702-3062
Vitalij NovickijDepartment of Immunology, State Research Institute Centre for Innovative Medicine, 13102 Vilnius, Lithuania.ORCID 0000-0001-6147-956X
Irutė GirkontaitėDepartment of Immunology, State Research Institute Centre for Innovative Medicine, 13102 Vilnius, Lithuania.ORCID 0000-0002-3659-3202
State Research Institute Centre for Innovative Medicine · LTVilnius Gediminas Technical University · LTKarolinska Institutet · SE

Funding

Lietuvos Mokslo Taryba S-LL-21-4
6 · The paper itself

Abstract

In this work, a time-dependent and time-independent study on bleomycin-based high-frequency nsECT (3.5 kV/cm × 200 pulses) for the elimination of LLC1 tumours in C57BL/6J mice is performed. We show the efficiency of nsECT (200 ns and 700 ns delivered at 1 kHz and 1 MHz) for the elimination of tumours in mice and increase of their survival. The dynamics of the immunomodulatory effects were observed after electrochemotherapy by investigating immune cell populations and antitumour antibodies at different timepoints after the treatment. ECT treatment resulted in an increased percentage of CD4

Indexed as

anticancerbleomycinelectrochemotherapyelectroporationhumoral and cellular immunityimmunologyimmunomodulationin vivonanosecondpulsed electric fields

Identifiers

PMID36551739
PMCPMC9776811
OpenAlexW4312140611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.